Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
about
MicroRNA Targeting to Modulate Tumor MicroenvironmentThe Emerging Role of miRNAs in HTLV-1 Infection and ATLL PathogenesisNanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatmentsiRNA Delivery Strategies: A Comprehensive Review of Recent Developments.MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma.Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repairTargeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.Preparation of poly(β-L-malic acid)-based charge-conversional nanoconjugates for tumor-specific uptake and cellular deliveryMultifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian CancerPolyetherimide-grafted Fe₃O₄@SiO2₂ nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging.Gemini Surfactants Based on Bis-Imidazolium Alkoxy Derivatives as Effective Agents for Delivery of Nucleic Acids: A Structural and Spectroscopic StudyDNA Polyplexes as Combinatory Drug Carriers of Doxorubicin and Cisplatin: An in Vitro Study.Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.Surface-mediated delivery of siRNA from fibrin hydrogels for knockdown of the BMP-2 binding antagonist noggin.Endothelial cell-targeted pVEGF165 polyplex plays a pivotal role in inhibiting intimal thickening after vascular injury.Effect of miR-200b on retinal endothelial cell function under high glucose environment.Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery SystemsRegulator role of HPV E7 protein on miR-21 expression in cervical carcinoma cells and its functional implication.Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplexMultifunctional selenium nanoparticles as carriers of HSP70 siRNA to induce apoptosis of HepG2 cells.Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA.Polyethyleneimine-coated quantum dots for miRNA delivery and its enhanced suppression in HepG2 cellsInduction of K562 Cell Apoptosis by As4S4 via Down-Regulating miR181.Multifunctional Nanographene Oxide for Targeted Gene-Mediated Thermochemotherapy of Drug-resistant Tumour.MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.Cytosolic co-delivery of miRNA-34a and docetaxel with core-shell nanocarriers via caveolae-mediated pathway for the treatment of metastatic breast cancer.Pleiotropic Role of Dietary Phytochemicals in Cancer: Emerging Perspectives for Combinational Therapy.Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicinesInhibition of cell proliferation through an ATP-responsive co-delivery system of doxorubicin and Bcl-2 siRNA.Cancer stem cells and personalized cancer nanomedicine.Redox-Activatable ATP-Depleting Micelles with Dual Modulation Characteristics for Multidrug-Resistant Cancer Therapy.KIF26B, a novel oncogene, promotes proliferation and metastasis by activating the VEGF pathway in gastric cancer.MiR-15b mediates liver cancer cells proliferation through targeting BCL-2.Expression and functional perspectives of miR-184 in pancreatic ductal adenocarcinoma.Oligonucleotide-based theranostic nanoparticles in cancer therapy.Effect of miR-503 Down-Regulation on Growth and Invasion of Esophagus Carcinoma and Related Immune Function.Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer.Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
P2860
Q26770275-04F314FF-4E30-410A-99EC-9E0A4B2A621BQ26800055-92FC40E2-C332-40CA-A52D-70A4054CC50AQ26866566-D731D086-54F9-47FE-AE05-FA5DEC41756EQ33611947-4CE77526-1F02-49CD-BE55-46DF7C42D084Q33635350-A5C7B815-DCBD-4740-B212-D114A3B604DEQ33635355-50F773E2-44FF-4584-8879-109BF480E8E0Q33709432-D1EF58B5-27AB-4596-A6BA-5E38FC352981Q35100982-FD6E89CC-D2BF-4D9F-B2DE-D69A23159C76Q35189737-E028267A-F935-4F90-953A-66C71A83B31DQ35374920-5DE6B129-8E84-4CFC-86B5-D9A12809A535Q35831166-750ABE5C-5555-46B0-858A-C6273A55E1E7Q35862401-DDB6EADC-53FA-412A-AC2F-975D344C88D9Q35912011-C4F64A14-E268-44AA-888E-39F42C595EC5Q35914942-55F073E8-625E-46C9-BCC2-3271E2A42312Q36037573-7F36ADB4-E2FE-4676-BDF6-09973AE22D48Q36094154-5C87E102-F146-4421-B80E-ADE287BB325EQ36261415-0435FF91-D3A1-4526-A677-C8EA23D63997Q36341433-67F503EB-89A8-423E-8AFA-88E8F9AFC142Q36511730-9AAB7EA0-CB4B-479B-8EFD-D090883FB306Q36776863-852F1EEC-283A-49EA-9900-B3405907749BQ37082794-FD69EA3C-F9B0-458A-A3FE-8D322C29B8D5Q37194157-C9069FD1-71EE-4B58-8E6E-C955B734C959Q37426859-8F96A35A-9974-4C10-8CC7-9C985B463ACCQ37591850-4340156D-717C-4184-A43B-8A3ED184C186Q37685914-8DCED33A-3A14-46F5-B27D-77DF55F9A5AAQ37693388-CB0D0A3E-DB67-4D2A-834F-9A87C784F43EQ37739791-B73470F7-3386-41C6-87A3-595D8586D3A9Q38584742-0A72D411-A3DA-4375-9898-A7569398BBE3Q38674444-A11B4ECA-42F9-4305-9FD9-4C452BD7CCD2Q38696439-83028E0F-F5C4-43E1-B1D4-B7D5C877B62DQ38702970-931772DA-414C-4878-B5C4-AE398850DB9AQ38718358-80B063AF-77DF-4651-81B7-0C6965B8D0A0Q38743870-EE80BD70-AE3C-46CD-B163-934A6E2EF659Q38793586-07CEB61F-F3D0-446D-A7F5-F6F1430046D9Q38807225-6E6B9C09-1C4D-4EF7-B970-B4E8BAEEA0C2Q38814327-4A9718AE-926E-443C-86F4-ADCD15B61926Q38818686-2FC8CB3D-4AFD-4F23-A773-3D678CA277FCQ38822775-D040B104-B266-4B18-AFAC-CBF588C36A33Q38828904-9CE4069F-21A7-4665-A551-EA21D0AEB712Q38833453-CCF34DC5-5712-430D-941F-651CF0EDC93E
P2860
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Nanocarrier mediated delivery ...... current progress and advances.
@ast
Nanocarrier mediated delivery ...... current progress and advances.
@en
Nanocarrier mediated delivery ...... current progress and advances.
@nl
type
label
Nanocarrier mediated delivery ...... current progress and advances.
@ast
Nanocarrier mediated delivery ...... current progress and advances.
@en
Nanocarrier mediated delivery ...... current progress and advances.
@nl
prefLabel
Nanocarrier mediated delivery ...... current progress and advances.
@ast
Nanocarrier mediated delivery ...... current progress and advances.
@en
Nanocarrier mediated delivery ...... current progress and advances.
@nl
P2093
P2860
P1476
Nanocarrier mediated delivery ...... current progress and advances.
@en
P2093
Mahavir B Chougule
Nishant S Gandhi
Rakesh K Tekade
P2860
P304
P356
10.1016/J.JCONREL.2014.09.001
P407
P577
2014-09-07T00:00:00Z